Protein Microarray System for Rheumatiod Arthritis Diagnosis

描述（由申请人提供）：类风湿性关节炎（RA）和其他自身免疫性疾病的诊断是一项复杂的挑战，结合了一系列生理线索和分子检测的解释。传统上，放射学已被用于测量RA进展。RA和相关疾病的体外诊断测试几乎完全由单一标记物测试组成。存在对基于生物标志物的改进的诊断以表征自身免疫性疾病中的疾病类型、状态、进展和对治疗的响应的公认但未满足的需求。我们建议开发一个集成的生物分析平台和一个临床研究计划，以促进患者样本的综合差异表型的基础上，并行检测多种生物标志物，当解释为一种模式时，将导致高度预测性和准确的测定。从这种先进的蛋白质分子诊断方法获得的整体临床图片将为临床医生提供一个强大的工具，用于早期检测，分类和预后，评估治疗和监测复发，在治疗自身免疫性疾病。反过来，这将导致改善患者护理，更好的结果和降低患者护理成本。拟议中的系统将包括三个关键要素：仪器，蛋白质芯片微阵列盒，和模式识别软件进行分析。靶向蛋白质生物标志物的高度平行检测基于我们称为光栅耦合表面等离子体共振成像（GCSPRI）的先进的无标记检测技术。这种基于芯片的技术可以在极少量的样品体积（约5 - 50升）中以接近实时的方式同时经济高效地测量数百种分析物。长期目标（在第二阶段结束时）是建立必要的基础，以便能够迅速获得FDA的批准。第一阶段（两年）的更有限的目标是开发一个由仪器和试剂盒组成的集成原型生物分析诊断平台，并开发和验证一种芯片，用于检测人体样本中相关分析物的存在。第一阶段开发的平台将用于第二阶段的人体临床研究。7.拟议的研究旨在开发类风湿性关节炎和其他自身免疫性疾病的改进诊断方法，这些疾病影响超过5000万美国人，是死亡和残疾的主要原因。预期的产品有望改善治疗，降低发病率，提高这些疾病患者的生活质量。

DESCRIPTION (provided by applicant): The diagnosis of rheumatoid arthritis (RA) and other autoimmune disease is a complex challenge that combines the interpretation of a range of physiological cues and molecular assays. Traditionally, radiography has been used to measure RA progression. In vitro diagnostic tests for RA and related diseases consist almost exclusively of single marker tests. There is a well-recognized but unmet need for improved diagnostics based on biological markers to characterize disease type, status, progression, and response to therapy in autoimmune diseases. We are proposing to develop an integrated bioanalytical platform and a clinical research program to facilitate comprehensive differential phenotyping of patient samples on the basis of parallel detection of multiple biomarkers, which when interpreted as a pattern will result in highly predictive and accurate assays. The holistic clinical picture obtained from this advanced protein molecular diagnostic approach will provide the clinician with a powerful tool for early detection, classification, and prognosis, assessment of therapy and monitoring of recurrence, in the treatment of autoimmune disease. This, in turn, should lead to improved patient care, better outcomes and reduced patient care costs. The proposed system will consist of three key elements: an instrument, a protein chip microarray cartridge, and pattern recognition software for analysis. Highly parallel detection of the targeted protein biomarkers is based on an advanced label-free detection technology that we refer to as Grating-Coupled Surface Plasmon Resonance Imaging (GCSPRI). This chip-based technology makes it possible to cost-effectively measure hundreds of analytes simultaneously in near-real time in minute sample volumes (~5 - 50 ¿L). The long-term goal (at the end of Phase II) is to have developed the necessary foundation to be able to proceed expeditiously with FDA approval. The more limited goals of the Phase I (two years) are to develop an integrated prototype bioanalytical diagnostic platform consisting of an instrument and reagent cartridge and to develop and validate a chip designed to assay the presence of relevant analytes in human samples. The platform developed in Phase I would be used in Phase II for human clinical studies. 7. Project Narrative The proposed research aims to develop improved diagnostic methods for rheumatoid arthritis and other autoimmune diseases which affect over 50 million Americans and are a leading cause of death and disability. Anticipated products are expected to improve treatment, reduce morbidity and improve the quality of life of patients suffering from these diseases.